Sennosides
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Sennosides: From Constipation (Laxative Use) to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Sennosides are stimulant laxatives that act on the colon. The data compiled for this report lists no approved indication text, but the products are marketed as laxatives. The TxGNN model predicts they may be effective for hypotrichosis simplex of the scalp, but 0 clinical trials and 0 publications currently support this prediction. It is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Laxative (inferred from product names; no approved indication text available) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licences) |
| Number of NDAs | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sennosides are anthraquinone stimulant laxatives that act on the colonic mucosa through their active metabolite rheinanthrone. Their efficacy relates to bowel function, not to hair biology.
No mechanistic link to hair follicle biology or to the genetic causes of hypotrichosis simplex (for example CDSN, APCDD1 and RPL21 variants) has been established. The high score is a model prediction only.
The other five predictions (congenital hypotrichosis milia, diffuse alopecia areata, open-angle glaucoma, primary hereditary glaucoma and alopecia) all score between 0.991 and 0.993 and also lack supporting evidence. This clustering suggests a graph-proximity artifact rather than a real signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M007 (cancelled) | Senna Laxative (Target Corporation) | Tablet | Not stated |
| 505G(a)(3) (cancelled) | Laxative (Army and Air Force Exchange Service) | Tablet, film coated | Not stated |
Safety Considerations
Please refer to the package insert for safety information.
No drug-drug interaction records were found, and no contraindication edges were identified in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications, and no plausible mechanism links a stimulant laxative to hair loss. Neither of the two US licences is currently valid.
To proceed, the following is needed:
- Mechanism of action data, to test whether any biological link to hair follicle biology exists
- Package insert warnings and contraindications, which are a blocking gap for safety screening
- Preclinical or mechanistic studies, since none currently exist
- Route compatibility assessment, since the available oral forms may not suit a scalp indication
- Review of the other predicted indications for any with better support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.